FES PET

DEVICE2 trials

Sponsors

University Medical Center Groningen, Centre Georges Francois Leclerc

Conditions

Breast CancerFES TEP in Detection of Estrogen Receptors

Phase 2

Palbociclib and FES PET

CompletedNCT02806050

University Medical Center GroningenBreast Cancer

Start: 2016-09-16End: 2022-09-28Updated: 2022-10-12

Unknown Phase

Evaluation of the Unconformity of the Hormonal Status of Metastatic Lesions During a First Relapse of Breast Cancer Initially Expressing Estrogen Receptors: a Pilot Study on the Interest of PET With FES

RecruitingNCT03873428

Centre Georges Francois LeclercFES TEP in Detection of Estrogen Receptors

Start: 2021-10-18End: 2025-10-18Target: 25Updated: 2024-02-13

Related Papers

Molecular imaging to identify patients with metastatic breast cancer who benefit from endocrine treatment combined with cyclin-dependent kinase inhibition.

2019-12-2852 citations